SOURCE: BioCentury Publications, Inc.

BioCentury Publications, Inc.

March 27, 2014 13:36 ET

BioCentury Launches the Third Decade of Future Leaders in the Biotech Industry

Expanded Slate Offers Differentiated Products, Upcoming Milestones and Over 100 Unpartnered Assets

REDWOOD CITY, CA and NEW YORK, NY--(Marketwired - Mar 27, 2014) - BioCentury will convene the 21st Annual Future Leaders in the Biotech Industry in New York City on Friday, March 28th at 8 a.m. at the Millennium Broadway Hotel & Conference Center.

The event showcases a full slate of 57 biopharma companies hand-picked on the basis of investor validation, upcoming milestones, unpartnered assets and innovative science, informed by BioCentury's business intelligence platform.

Over 650 life science investment professionals and pharmaceutical business development and licensing executives have pre-registered for the event. Walk-up registration is available starting at 7:15 a.m. on Friday, March 28th on the 4th floor of the Millennium Broadway Conference Center, 133 West 44th Street.

The Future Leaders Class of 2014 has been doing its part to keep the biotech bull market running. The 29 public and 28 private companies have raised $6.7 billion in capital, including $3.1 billion since the beginning of 2013.

Public companies at Future Leaders are collectively up 43% this year, easily out-distancing the 16% jump in the BioCentury 100 Index as well as the 2% decline in the Dow Jones Industrial Average and 1% gain in the S&P 500. Over that same period, the aggregate market cap of the Future Leaders public companies has grown by $4.2 billion, from $9.9 billion to $14.1 billion.

This year's conference introduces a new Next Wave track of 15 early stage, privately held companies. The Next Wave track showcases platform plays and development companies advancing their assets to the clinic.

The Class of 2014 also features select IPO stories and public companies nearing key Phase II and III milestones in addition to international companies approaching value inflection points. Disease areas covered by the Class of 2014 include cancer, infectious disease, and neurological, cardiovascular and autoimmune disorders.

The Class of 2014 companies comprise a solid mix of innovative science and platform assets and provide ample partnering opportunities.

These Future Leaders have 11 marketed products, 15 products in Phase III/Registration, 53 products in Phase II development, 56 products in Phase I and at least 88 products in preclinical development. More than 100 products are currently unpartnered.

"While we know that bull markets can't last forever, they typically don't end when companies have strong balance sheets and upcoming transformational milestones," said BioCentury Publisher Eric Pierce. "The Future Leaders Class of 2014 is aiming to show how they can create more value for investors going forward."

The 2014 Presenting Companies
Presenting companies were screened by BioCentury's industry analysts using BioCentury's BCIQ online business intelligence platform. The result is an independently selected mix of companies with proven fundraising capacity, the prospect for key partnerships and proximity to potentially transformational milestones.

Presenting Companies

Acceleron Pharma Inc. (XLRN)
Actinium Pharmaceuticals Inc. (ATNM)
ActoGeniX N.V.
arGEN-X B.V.
Argos Therapeutics Inc. (ARGS)
Auspex Pharmaceuticals Inc. (ASPX)
Blueprint Medicines
Celladon Corp. (CLDN)
Cempra Inc. (CEMP)
Cytos Biotechnology AG (CYTN)
Dicerna Pharmaceuticals Inc. (DRNA)
Effector Therapeutics Inc.
Eleven Biotherapeutics Inc. (EBIO)
Esperion Therapeutics Inc. (ESPR)
Evotec AG (EVT)
Fibrocell Science Inc. (FCSC)
Five Prime Therapeutics Inc. (FPRX)
Galena Biopharma Inc. (GALE)
Genfit S.A. (ALGFT)
Heptares Therapeutics Ltd.
Horizon Pharma Inc. (HZNP)
Igenica Inc.
Iroko Pharmaceuticals LLC
Juno Therapeutics Inc.
KaloBios Pharmaceuticals Inc. (KBIO)
Labrys Biologics Inc.
Lion Biotechnologies Inc. (LBIO)
Moderna Therapeutics Inc.
NeoStem Inc. (NBS)
Omeros Corp. (OMER)
Opsona Therapeutics Ltd.
Orexo AB (ORX; ORXOY)
PaxVax Inc.
Prana Biotechnology Ltd. (PBT; PRAN)
Receptos Inc. (RCPT)
Regado Biosciences Inc. (RGDO)
Regimmune Corp.
Sutro Biopharma Inc.
Tetraphase Pharmaceuticals Inc. (TTPH)
Ultragenyx Pharmaceutical Inc. (RARE)
uniQure N.V. (QURE)
Xencor Inc. (XNCR)
Ziopharm Oncology Inc. (ZIOP)

Next Wave Companies

Adaptimmune Ltd.
Aduro BioTech Inc.
Alzheon Inc.
Arcturus Therapeutics Inc.
Cerecor Inc.
Civitas Therapeutics Inc.
Clementia Pharmaceuticals Inc.
Nora Therapeutics Inc.
Protagonist Therapeutics Inc.
scPharmaceuticals LLC
Seres Health Inc.
Syros Pharmaceuticals Inc.
TauRx Pharmaceuticals Ltd.
viDA Therapeutics Inc.

See the Presenting Company schedule at http://www.biocentury.com/Data/NewsCenter2/Conferences/ConferencesFiles/FL14schedule.pdf.

Top Sponsors Demonstrate Long-Term Commitment to Industry
The prestigious group of 2014 sponsors is anchored by Gold Sponsors Brinson Patrick Securities and WBB Securities; Silver Sponsors AstraZeneca, Johnson & Johnson, Laidlaw & Company and Tiberend Strategic Advisors; and luncheon sponsor Flanders Investment & Trade.

This premier Wall Street event is one of two annual U.S. investor conferences organized by BioCentury. The next Wall Street conference, the 21st Annual NewsMakers in the Biotech Industry, will take place in New York City on September 26, 2014, at the Millennium Broadway Hotel & Conference Center.

BioCentury also co-organizes BioEquity Europe, which will take place in Amsterdam, May 21 - 22, 2014. The 15th Annual BioEquity Europe will be the premier event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for business development and licensing professionals from pharmaceutical companies to assess top partnering and licensing prospects.

About BioCentury
Since 1993, BioCentury Publications, Inc. has provided essential biopharma industry intelligence to a global audience of biotech and pharmaceutical executives, investors, regulators, public policy makers and the scientific community. This audience has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia.

BioCentury's titles include the flagship BioCentury®, the Bernstein Report on BioBusiness; its SciBX: Science-Business eXchange™ translational science partnership with Nature Publishing Group; and its BioCentury Extra™ online daily newspaper. These timely journals are backed by BCIQ: BioCentury Online Intelligence™, an online business intelligence resource. BioCentury also produces its BioCentury This Week biotech public affairs television program in partnership with the Gannett-owned WUSA9 CBS affiliate in Washington, D.C. The program is aired in Washington each Sunday, on selected Public Broadcasting System member stations and distributed globally online at www.biocenturytv.com.

For more information, visit www.biocentury.com and www.biocenturytv.com.